0.88
+0.01739999(+2.03%)
Currency In USD
| Previous Close | 0.86 |
| Open | 0.86 |
| Day High | 0.88 |
| Day Low | 0.84 |
| 52-Week High | 3.87 |
| 52-Week Low | 0.39 |
| Volume | 705,683 |
| Average Volume | 1.15M |
| Market Cap | 57.16M |
| PE | -3.24 |
| EPS | -0.27 |
| Moving Average 50 Days | 0.93 |
| Moving Average 200 Days | 1.15 |
| Change | 0.02 |
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
GlobeNewswire Inc.
Jan 28, 2026 12:00 PM GMT
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the p
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus subcutaneous injection - SAN JOSE, Calif., Jan. 08, 2026 (
Rani Therapeutics to Participate in the Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 9:05 PM GMT
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that